Artificial Intelligence Platform Demonstrates High Adherence in Patients Receiving Fixed-Dose Ledipasvir and Sofosbuvir: A Pilot Study | Zendy

Alain H. Litwin | Zendy; Laura Shafner | Zendy; Brianna L. Norton | Zendy; Matthew J. Akiyama | Zendy; Linda Agyemang | Zendy; Mercedes Guzman | Zendy; Tatiana Vera | Zendy; Moonseong Heo | Zendy

Open Access

Artificial Intelligence Platform Demonstrates High Adherence in Patients Receiving Fixed-Dose Ledipasvir and Sofosbuvir: A Pilot Study

Author(s) -

Alain H. Litwin,

Laura Shafner,

Brianna L. Norton,

Matthew J. Akiyama,

Linda Agyemang,

Mercedes Guzman,

Tatiana Vera,

Moonseong Heo

Publication year - 2020

Publication title -

open forum infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.546

H-Index - 35

ISSN - 2328-8957

DOI - 10.1093/ofid/ofaa290

Subject(s) - medicine , sofosbuvir , ledipasvir , hepatitis c , hepatitis c virus , fixed dose combination , medication adherence , virology , virus , ribavirin

This study evaluated health outcomes among people who inject drugs infected with hepatitis C virus using an artificial intelligence platform. Mean (SD) cumulative adherence (visual confirmation of administration) was 91.3% (SD=10.5%). Most subjects (88.2%) achieved ≥ 80% adherence to treatment and 88.2% (15 of 17) achieved a sustained virologic response.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research